DATE – Talk Bio

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

2 days ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease

Recent Developments in Building Measurable Patient Support Programs (2025)

3 days ago talkbio0Tagged 2025, care activity, collaborative healthcare, Efficiency, Financial cost, measurable outcomes, Medicare reforms, Programs - Publication Format, trends qualifier

patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care

Biopharma Layoffs Continue to Surge in First Half of 2025

1 week ago talkbio0Tagged Biopharma, biotech closures, Increase, Industry, layoffs, trends qualifier

biopharma; layoffs; 2025; workforce reductions; industry trends; biotech closures; year-over-year increase

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

4 weeks ago talkbio0Tagged CagriSema, Diabetes, eli lilly, Evaluate report, Mounjaro, Nordisk, Obesity, Ozempic, Pharmaceutical Sales, semaglutide, tirzepatide, top-selling drugs, Wegovy, Zepbound

diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast

Over One-Third of Biotechs Face Cash Crunch, EY 2025 Report Finds

4 weeks ago talkbio0Tagged Biological Science Disciplines, Biopharma, capital constraints, cash runway, EY, macroeconomic

biotech; EY report; cash runway; life sciences; capital constraints; biopharma; 2025; macroeconomic uncertainty

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

1 month ago talkbio0Tagged 2025, Artificial Intelligence, ASCO, Big Data, campaigns, Cancer Research, Clinical Oncology, erbB-2 Receptor, Malignant neoplasm of breast, Malignant neoplasm of lung

ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines

Metsera Reports Once-Monthly Amylin Analogue Matches GLP-1 Efficacy in Early Phase 1 Results

1 month ago talkbio0Tagged Amylin, Clinical Trials, Glucagon-Like Peptide 1, MET-233i, Metsera, Obesity, once-monthly, Phase 1 (qualifier value), Weight-Loss

Metsera; MET-233i; amylin; obesity; weight-loss; GLP-1; once-monthly; clinical trial; phase 1

ASCO 2025: Amgen’s Imdelltra Cuts Small Cell Lung Cancer Death Risk by 40% Versus Chemo

2 months ago talkbio0Tagged 2025, amgen, ASCO, death risk reduction, Imdelltra, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Small cell carcinoma of lung, tarlatamab-dlle

ASCO 2025; Amgen; Imdelltra; tarlatamab-dlle; lung cancer; small cell lung cancer; death risk reduction; overall survival; Phase 3 trial

Regeneron Licenses Hansoh’s GLP-1/GIP Obesity Drug to Compete with Zepbound

2 months ago talkbio0Tagged Biopharma, eli lilly, GLP-1/GIP receptor agonist, Hansoh Pharmaceuticals, HS-20094, Licensing Deal, Obesity, Regeneron, Zepbound

Regeneron; Hansoh Pharmaceuticals; HS-20094; GLP-1/GIP receptor agonist; obesity drug; Zepbound; Eli Lilly; obesity treatment; licensing deal; biopharma

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

2 months ago talkbio0Tagged 2025, Alfa, Antibody Therapy, ASCO, Bicara Therapeutics, Cancer of Neck, Head, Keytruda, Overall Survival, PD-L1, tumor shrinkage

ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage